Logo

CASI Pharmaceuticals, Inc.

CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel… read more

Healthcare

Biotechnology

27 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.31

Price

-13.30%

-$0.20

Market Cap

$20.296m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$31.564m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$46.890m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$3.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$20.310m

$31.202m

Assets

$51.512m

Liabilities

$18.734m

Debt
Debt to Assets

60.0%

-0.5x

Debt to EBITDA
Free Cash Flow

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases